Tags

Type your tag names separated by a space and hit enter

Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment.
Curr Drug Deliv. 2020; 17(7):613-621.CD

Abstract

BACKGROUND

Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored.

METHODS

The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site.

RESULTS

Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice.

CONCLUSION

It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc).

Authors+Show Affiliations

Department of Physics, Maulana Azad National Institute of Technology, Bhopal, India.Department of Physics, Maulana Azad National Institute of Technology, Bhopal, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32384028

Citation

Rajawat, Shweta, and Manzar M. Malik. "Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment." Current Drug Delivery, vol. 17, no. 7, 2020, pp. 613-621.
Rajawat S, Malik MM. Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment. Curr Drug Deliv. 2020;17(7):613-621.
Rajawat, S., & Malik, M. M. (2020). Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment. Current Drug Delivery, 17(7), 613-621. https://doi.org/10.2174/1567201817666200508095241
Rajawat S, Malik MM. Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment. Curr Drug Deliv. 2020;17(7):613-621. PubMed PMID: 32384028.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment. AU - Rajawat,Shweta, AU - Malik,Manzar M, PY - 2020/01/30/received PY - 2020/03/11/revised PY - 2020/04/07/accepted PY - 2020/5/10/pubmed PY - 2020/5/10/medline PY - 2020/5/9/entrez KW - Adriamycin KW - MCF-7 breast cancer KW - black tea leaves extract KW - multi surface coatings KW - potato extract KW - silver nanoparticles KW - targeted delivery SP - 613 EP - 621 JF - Current drug delivery JO - Curr Drug Deliv VL - 17 IS - 7 N2 - BACKGROUND: Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored. METHODS: The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site. RESULTS: Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice. CONCLUSION: It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc). SN - 1875-5704 UR - https://www.unboundmedicine.com/medline/citation/32384028/Targeted_Delivery_of_Colloidal_Silver_for_MCF-7_Breast_Cancer_Treatment L2 - https://www.eurekaselect.com/181779/article DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.